Dihexa (PNB-0408; N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a synthetic, metabolically stabilized peptidomimetic derived from angiotensin IV, built on a tyrosine-isoleucine core. It is a frequent subject of laboratory research and is supplied as a lyophilized powder for research use only.
In published in vitro and preclinical research, Dihexa has been studied in connection with binding to hepatocyte growth factor (HGF) and positive allosteric modulation of HGF activity at its receptor, c-Met (a receptor tyrosine kinase). These studies are conducted in cell-culture and animal research models. The findings derive from laboratory research and do not describe or imply any effect, benefit, or use in humans or animals.
Published literature has examined Dihexa across a range of cell-culture and animal research models relating to HGF/c-Met receptor signaling and synaptogenesis biology. These reports reflect controlled laboratory conditions only and do not translate to dosing, treatment, or applications in any other context. Its mechanism is studied alongside related research compounds such as Semax, P21, and Selank.
For further reading, see published research on Dihexa on PubMed.
Product Specifications
| CAS Number | 1401708-83-5 |
| Molecular Formula | C₂₇H₄₄N₄O₅ |
| Molecular Weight | ~504.66 g/mol |
| Structure | Angiotensin IV-derived peptidomimetic (Tyr-Ile core) |
| Synonyms | PNB-0408, Hexanoyl-Tyr-Ile-Ahx-NH₂ |
| Purity | ≥99% by HPLC | COA available |
| Physical Form | Lyophilized powder |
| Storage Conditions | Store at −20°C; protect from light and moisture |
For Research Use Only. Not for use in diagnostic, therapeutic, or human or animal in-vivo procedures. This product is sold exclusively for in-vitro laboratory research use. It is not a drug, dietary supplement, food, or cosmetic and has not been approved by the U.S. Food and Drug Administration for any use. Not intended to diagnose, treat, cure, mitigate, or prevent any disease. Not for human or animal consumption.
Reviews
There are no reviews yet.